MLYS — MINERALYS THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
MLYS FAQ
What is MLYS's ROE?
MINERALYS THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -23.78%.
What is MLYS's dividend yield?
MINERALYS THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is MLYS's Deepscope Quality Score?
Deepscope rates MLYS's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MLYS?
Deepscope's AI Timing Score for MLYS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MLYS belong to?
MINERALYS THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 24.18
Price
1.68
(7.47%)
Day Change
|
|
|---|
MLYS Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 24.18 |
| PBV / Sector |
3.21 / 4.71
|
| Earning Per Share | -1.79 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
49.52 M
GREAT
|
| Average 1W Daily Value |
95.08 M
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
41% |
| Khả năng kiếm lợi nhuận |
|
37% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-10 09:43:49 |
| Symbol | MLYS |
| Name | MINERALYS THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 88.16 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,051.01 / 8,889.42 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 150 N. Radnor Chester Road, Radnor, PA, United States, 19087
Phone: 888 378 6240
Website: https://mineralystx.com
Employees: 76
Sector: Healthcare >> Biotechnology
Description: Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google